影像学评估乳腺癌新辅助化疗反应的研究进展

doi:10.11904/j.issn.1002-3070.2018.01.012

摘要/Abstract

摘要： 传统用于评估肿瘤对于新辅助化疗反应的常规成像方式有一定的局限性,功能成像能够早期预测新辅助化疗反应,从而个性化的指导治疗。但目前对于新辅助化疗随访患者的影像学评估方法并无标准。本文旨在讨论用于评价乳腺癌新辅助化疗患者化疗反应情况的各种影像学方法尤其是功能成像的准确性、优势、局限性和未来发展方向。

关键词: 乳腺癌, 新辅助化疗, 功能成像

Abstract: Traditionally,conventional imaging modalities used to assess neoplasms for neoadjuvant chemotherapy responses have their own limitations.Functional imaging can predict neoadjuvant chemotherapeutic responses early and thus guide personalized therapies.However,there is no standard method of imaging assessment for neoadjuvant chemotherapy follow-up.The aim of this article is to discuss the accuracy,advantages,limitations,and future directions of various imaging methods,especially functional imaging,for evaluating the response to chemotherapy in patients with breast neoadjuvant chemotherapy.

Key words: Breast cancer, Neoadjuvant chemotherapy, Functional image

中图分类号:

R737.9
R445

黎玉娇, 尚乃舰. 影像学评估乳腺癌新辅助化疗反应的研究进展[J]. 实用肿瘤学杂志, 2018, 32(1): 63-67.

LI Yujiao, SHANG Naijian. Research progress of imaging evaluation of neoadjuvant chemotherapy in breast cancer[J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(1): 63-67.

参考文献

1 Van la Parra RF,Kuerer HM.Selective elimination of breast cancer surgery in exceptional responders:historical perspective and current trials[J].Breast Cancer Res,2016,18(1):1-8.
2 Huber S,Wagner M,Zuna I,et al.Locally advanced breast carcinoma:evaluation of mammography in the prediction of residual disease after induction chemotherapy[J].Anticancer Res,2000,20(1):553-558.
3 Keune JD,Jeffe DB,Schootman M,et al.Accuracy of ultrasonography and mammography in predicting pathologic response after neoadjuvant chemotherapy for breast cancer[J].Am J Surg,2010,199(4):477-484.
4 Chagpar AB,Middleton LP,Sahin AA,et al.Accuracy of physical examination,ultrasonography,and mammography in predicting residual pathologic tumor size in patients treated with neoadjuvant chemotherapy[J].Ann Surg,2006,243(2):257-264.
5 Hylton NM,Blume JD,Bernreuter WK,et al.Locally advanced breast cancer:MR imaging for prediction of response to neoadjuvant chemotherapy-results from ACRIN 6657/I-SPY TRIAL[J].Radiology,2012,263(3):663-672.
6 Cho N,Im SA,Park IA,et al.Breast cancer:early prediction of response to neoadjuvant chemotherapy using parametric response maps for MR imaging[J].Radiology,2014,272(2):385-396.
7 Wu J,Gong G,Cui Y,et al.Intratumor partitioning and texture analysis of dynamic contrast-enhanced(DCE)-MRI identifies relevant tumor subregions to predict pathological response of breast cancer to neoadjuvant chemotherapy[J].J Magn Reson Imaging,2016,44(5):1107-1115.
8 Waugh SA,Purdie CA,Jordan LB,et al.Magnetic resonance imaging texture analysis classification of primary breast cancer[J].Eur Radiol,2016,26(2):322-330.
9 Park SH,Moon WK,Cho N,et al.Diffusion-weighted MR imaging:pretreatment prediction of response to neoadjuvant chemotherapy in patients with breast cancer[J].Radiology,2010,257(1):56-63.
10 Wu LM,Hu JN,Gu HY,et al.Can diffusion-weighted MR imaging and contrast-enhanced MR imaging precisely evaluate and predict pathological response to neoadjuvant chemotherapy in patients with breast cancer?[J].Breast Cancer Res Treat,2012,135(1):17-28.
11 Che S,Zhao X,Ou Y,et al.Role of the intravoxel incoherent iotion diffusion weighted imaging in the pre-treatment prediction and early response monitoring to neoadjuvant chemotherapy in locally advanced breast cancer[J].Medicine(Baltimore),2016,95(4):e2420.
12 Andrade WP,Lima EN,Osório CA,et al.Can FDG-PET/CT predict early response to neoadjuvant chemotherapy in breast cancer?[J].Eur J Surg Oncol,2013,39(12):1358-1363.
13 Wang Y,Zhang C,Liu J,et al.Is ¹⁸F-FDG PET accurate to predict neoadjuvant therapy response in breast cancer? A meta-analysis[J].Breast Cancer Res Treat,2012,131(2):357-369.
14 Groheux D,Majdoub M,Sanna A,et al.Early metabolic response to neoadjuvant treatment:FDG PET/CT criteria according to breast cancer subtype[J].Radiology,2015,277(2):358-371.
15 Berg WA,Madsen KS,Schilling K,et al.Breast cancer:comparative effectiveness of positron emission mammography and MR imaging in presurgical planning for the ipsilateral breast[J].Radiology,2011,258(1):59-72.
16 Xu HB,Li L,Xu Q.Tc-99m sestamibi scintimammography for the diagnosis of breast cancer:meta-analysis and meta-regression[J].Nucl Med Commun,2011,32(11):980-988.
17 Johnson N,Sorenson L,Bennetts L,et al.Breast-specific gamma imaging is a cost effective and efficacious imaging modality when compared with MRI[J].Am J Surg,2014,207(5):698-701.
18 Guo C,Zhang C,Liu J,et al.Is Tc-99m sestamibi scintimammography useful in the prediction of neoadjuvant chemotherapy responses in breast cancer? A systematic review and meta-analysis[J].Nucl Med Commun,2016,37(7):675-688.
19 Lee HS,Ko BS,Ahn SH,et al.Diagnostic performance of breast-specific gamma imaging in the assessment of residual tumor after neoadjuvant chemotherapy in breast cancer patients[J].Breast Cancer Res Treat,2014,145(1):91-100.
20 Mitchell D,Hruska CB,Boughey JC,et al.⁹⁹mTc-sestamibi using a direct conversion molecular breast imaging system to assess tumor response to neoadjuvant chemotherapy in women with locally advanced breast cancer[J].Clin Nucl Med,2013,38(12):949-956.
21 Hayashi M,Yamamoto Y,Ibusuki M,et al.Evaluation of tumor stiffness by elastography is predictive for pathologic complete response to neoadjuvant chemotherapy in patients with breast cancer[J].Ann Surg Oncol,2012,19(9):3042-3049.
22 Evans A,Armstrong S,Whelehan P,et al.Can shear-wave elastography predict response to neoadjuvant chemotherapy in women with invasive breast cancer?[J].Br J Cancer,2013,109(11):2798-2802.
23 Jing H,Cheng W,Li ZY,et al.Early evaluation of relative changes in tumor stiffness by shear wave elastography predicts the response to neoadjuvant chemotherapy in patients with breast cancer[J].J Ultrasound Med,2016,35(8):1619-1627.
24 Fujisawa T,Hirakata T,Yanagita Y,et al.The detection of pCR after PST by contrast-enhanced ultrasonography for breast cancer[J].Breast Cancer,2013,20(1):75-82.
25 Amioka A,Masumoto N,Gouda N,et al.Ability of contrast-enhanced ultrasonography to determine clinical responses of breast cancer to neoadjuvant chemotherapy[J].Jpn J Clin Oncol,2016,46(4):303-309.
26 Tran WT,Childs C,Chin L,et al.Multiparametric monitoring of chemotherapy treatment response in locally advanced breast cancer using quantitative ultrasound and diffuse optical spectroscopy[J].Oncotarget,2016,7(15):19762-19780.
27 Dominici LS,Negron Gonzalez VM,Buzdar AU,et al.Cytologically proven axillary lymph node metastases are eradicated in patients receiving preoperative chemotherapy with concurrent trastuzumab for HER2-positive breast cancer[J].Cancer,2010,116(12):2884-2889.
28 Hieken TJ,Boughey JC,Jones KN,et al.Imaging response and residual metastatic axillary lymph node disease after neoadjuvant chemotherapy for primary breast cancer[J].Ann Surg Oncol,2013,20(10):3199-3204.
29 Alvarado R,Yi M,Lepetross H,et al.The role for sentinel lymph node dissection after neoadjuvant chemotherapy in patients who present with node-positive breast cancer[J].Ann Surg Oncol,2012,19(10):3177-3184.

[1]	王晓雅,肖斌,廖扬,唐荣芝,孙朝晖,李林海. CXCR家族蛋白在不同乳腺癌亚型中的表达及临床预后分析[J]. 实用肿瘤学杂志, 2019, 33(3): 206-210.
[2]	李烁,张楠楠,李亮亮,龙志平,尹慧慧,赵亚双,王帆. 外周血白细胞PDE4C基因甲基化及环境因素交互作用与乳腺癌发病的关系[J]. 实用肿瘤学杂志, 2019, 33(3): 233-238.
[3]	李嘉琪,栾瑾微,张,玉,李香兰. 763例三阴性乳腺癌临床病理特征及复发、转移影响因素分析[J]. 实用肿瘤学杂志, 2019, 33(3): 244-249.
[4]	陈艳波, 孔德嘉, 张金锋, 马志刚. 乳腺癌患者CYP2D6基因多态性与他莫昔芬代谢相关性研究[J]. 实用肿瘤学杂志, 2019, 33(2): 110-114.
[5]	孙江宏, 郝明珠, 姜丹, 国飞, 李晓梅. 乳腺炎、良性增生及乳腺癌FFDM鉴别诊断思路[J]. 实用肿瘤学杂志, 2019, 33(2): 139-141.
[6]	马志杰, 王帆, 赵亚双. 乳腺癌化疗患者生存质量及影响因素分析[J]. 实用肿瘤学杂志, 2019, 33(2): 149-154.
[7]	马质莹, 尚乃舰, 蔡妙田, 沈阳, 姜智允. 孕激素及雌激素受体阳性乳腺癌HER-2受体与钼靶影像学特征及临床病理学特征的相关性分析[J]. 实用肿瘤学杂志, 2019, 33(1): 47-51.
[8]	何煦, 叶尚勉, 董丹丹, 李科. HLA-G在乳腺癌中的表达及意义[J]. 实用肿瘤学杂志, 2018, 32(5): 410-414.
[9]	林荣杰, 尹航, 周云峰. ON123300对ER阳性人乳腺癌MCF-7细胞的影响及机制研究[J]. 实用肿瘤学杂志, 2018, 32(3): 193-197.
[10]	李林(综述), 李志高(审校). 二甲双胍与不同分子亚型乳腺癌的关系[J]. 实用肿瘤学杂志, 2018, 32(3): 267-270.
[11]	郑伟, 许守平, 庞达. 长链非编码RNA Linc00152在泛癌中表达、预后及功能研究[J]. 实用肿瘤学杂志, 2018, 32(1): 7-13.
[12]	殷玉莲, 张卫红, 周悦, 叶媚娜, 陈红风. ERα基因单核苷酸多态性与乳腺癌应用芳香化酶抑制剂引发骨丢失的相关性研究[J]. 实用肿瘤学杂志, 2018, 32(1): 14-18.
[13]	陈琢, 孔艺然. 沉默UHRF1对乳腺癌细胞增殖和转移的影响[J]. 实用肿瘤学杂志, 2017, 31(6): 512-518.
[14]	李红阳, 孙亮, 姜醒, 苑光军, 刘艳. 蝙蝠葛碱在人乳腺癌MCF-7细胞对5氟尿嘧啶敏感性的研究[J]. 实用肿瘤学杂志, 2017, 31(5): 385-389.
[15]	罗佳宁, 郝春成, 张建鑫, 卢江岳, 葛晓峰. 术后辅助放疗对三阴性乳腺癌患者预后的影响[J]. 实用肿瘤学杂志, 2017, 31(5): 411-416.